Home / Market News / $ABBV
benzinga Corporate Catalyst Impact 75/100 ● positive

AbbVie Says All Three Zumilokibart Dose Regimens Met Primary Endpoint With Significantly Greater EASI-75 Response Vs Placebo At Week 16 In Phase 2 APEX Part B Atopic Dermatitis Study

Sep 30, 2026, 6:54 AM UTC · Primary ticker $ABBV

AbbVie announced positive Phase 2 results for its atopic dermatitis drug, zumilokibart, with all dose regimens meeting the primary endpoint. This successful trial progression, particularly the selection of a mid-dose for Phase 3, signals a significant step forward in the drug's development and potential market entry.

AbbVie reported that its investigational drug, zumilokibart, for atopic dermatitis, successfully met its primary endpoint in a Phase 2 study. All three dose regimens showed significantly greater EASI-75 response rates compared to placebo, with the mid-dose selected for Phase 3 development. This is a significant positive for AbbVie as it de-risks a key pipeline asset and strengthens its position in the dermatology market. For competitors like Eli Lilly (LLY) and Regeneron (REGN), who have established or developing treatments for atopic dermatitis, this represents increased future competition. Short-term, ABBV could see a positive reaction, while long-term, it positions the company for a potential new blockbuster drug, impacting the competitive landscape.

$ABBV positive Successful drug trial progression
$LLY negative Increased competition in atopic dermatitis market
$REGN negative Increased competition in atopic dermatitis market
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.